Abstract | PURPOSE OF REVIEW: To raise awareness of and inform evidence-based practice regarding medical and behavioral interventions for antipsychotic medication-induced metabolic abnormalities. RECENT FINDINGS: The current literature indicates that individuals with severe and persistent mental illness have significantly worse health outcomes and premature mortality than the general population, owing to a combination of under-recognition and treatment of medical risk factors, reduced access to care, sedentary lifestyle and poor diet, and the potential contribution of adverse metabolic side effects of antipsychotic medications such as weight gain, hyperglycemia and dyslipidemia. A combination of administrative, behavioral and medical approaches to addressing these medical risks may be more effective than any one of these approaches alone. SUMMARY:
|
Authors | Jonathan M Amiel, Christina V Mangurian, Rohan Ganguli, John W Newcomer |
Journal | Current opinion in psychiatry
(Curr Opin Psychiatry)
Vol. 21
Issue 6
Pg. 613-8
(Nov 2008)
ISSN: 1473-6578 [Electronic] United States |
PMID | 18852570
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Antipsychotic Agents
(adverse effects)
- Cardiovascular Diseases
(chemically induced, epidemiology, metabolism)
- Disease Progression
- Dyslipidemias
(chemically induced, epidemiology)
- Humans
- Hyperglycemia
(chemically induced, epidemiology)
- Mental Disorders
(drug therapy, psychology)
- Obesity
(chemically induced, epidemiology)
- Risk Factors
- Severity of Illness Index
|